- Home
- NTRA vs ES Comparison
NTRA vs ES Comparison
Compare NTRA & ES Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTRA
- ES
- Stock Information
- Founded
- NTRA 2003
- ES 1927
- Country
- NTRA United States
- ES United States
- Employees
- NTRA N/A
- ES N/A
- Industry
- NTRA Medical Specialities
- ES Electric Utilities: Central
- Sector
- NTRA Health Care
- ES Utilities
- Exchange
- NTRA Nasdaq
- ES Nasdaq
- Market Cap
- NTRA 27.0B
- ES 27.7B
- IPO Year
- NTRA 2015
- ES N/A
- Fundamental
- Price
- NTRA $205.15
- ES $73.55
- Analyst Decision
- NTRA Strong Buy
- ES Hold
- Analyst Count
- NTRA 16
- ES 12
- Target Price
- NTRA $220.38
- ES $72.09
- AVG Volume (30 Days)
- NTRA 1.4M
- ES 2.5M
- Earning Date
- NTRA 11-06-2025
- ES 11-04-2025
- Dividend Yield
- NTRA N/A
- ES 4.11%
- EPS Growth
- NTRA N/A
- ES N/A
- EPS
- NTRA N/A
- ES 3.65
- Revenue
- NTRA $2,116,676,000.00
- ES $13,148,536,000.00
- Revenue This Year
- NTRA $25.70
- ES $10.24
- Revenue Next Year
- NTRA $15.42
- ES $4.17
- P/E Ratio
- NTRA N/A
- ES $20.11
- Revenue Growth
- NTRA 38.17
- ES 13.12
- 52 Week Low
- NTRA $125.38
- ES $52.28
- 52 Week High
- NTRA $212.21
- ES $75.25
- Technical
- Relative Strength Index (RSI)
- NTRA 65.15
- ES 54.94
- Support Level
- NTRA $182.20
- ES $71.61
- Resistance Level
- NTRA $212.21
- ES $73.15
- Average True Range (ATR)
- NTRA 8.09
- ES 1.46
- MACD
- NTRA 0.00
- ES -0.22
- Stochastic Oscillator
- NTRA 75.84
- ES 55.12
About NTRA Natera Inc.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
About ES Eversource Energy (D/B/A)
Eversource Energy is a diversified holding company with subsidiaries that provide rate-regulated electric and gas distribution service to more than 4 million customers in the Northeast US. Eversource expanded its service territories with acquisitions of NStar (2012), Aquarion (2017), and Columbia Gas (2020). In 2024 Eversource exited its 50% partnership with European utility Orsted to develop 2 gigawatts of offshore wind projects in the Northeast US. The company exited most of its unregulated businesses in 2006.